Atopic Dermatitis Market Research Report present a detailed analysis of the market listing Atopic Dermatitis Epidemiology, Drug therapies and pipeline for study period from 2018-2030.

Atopic Dermatitis Market size, share, drugs, Atopic Dermatitis Research Report, Epidemiology and Companies.

Atopic Dermatitis (AD) Market

1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. SWOT Analysis
6. Atopic Dermatitis Market Overview at a Glance
6.1. Market Share (%) Distribution by Class of Therapies of Atopic Dermatitis in 2020
6.2. Market Share (%) Distribution by Class ofTherapies of Atopic Dermatitis in 2030
7. Disease Background and Overview
7.1. Signs and Symptoms
7.2. Causes and Triggers
7.3. Clinical presentation
7.4. Pathophysiology
7.5. Skin hypersensitivity &ndash; abnormalities of the horny cell layer
7.5.1. Mechanisms involved in inflammation
7.5.2. Pruritus
7.6. Biomarkers
7.6.1. Serum IgE levels
7.6.2. Peripheral eosinophil count
7.6.3. Serum lactate dehydrogenase level
7.6.4. Serum thymus and activation regulated chemokine level
7.7. Characteristics of eruption
7.7.1. Infancy (younger than 2 years)
7.7.2. Childhood/school-age (2&ndash;12 years old)
7.7.3. Adolescence/adulthood (13 years and older)
7.8. Differential diagnosis
7.9. Prevention and Management
7.10. Diagnosis
7.11. Diagnostic criteria for eczema
8. Treatment
8.1. Topical treatment
8.1.1. Emollients
8.1.2. Topical Corticosteroids (TCs)
8.1.3. Topical Calcineurin Inhibitors (TCIs)
8.2. Systemic Treatment
8.2.1. Immunosuppressants
8.2.2. Oral Corticosteroids
8.2.3. Interleukin Inhibitors
8.2.4. JAK inhibitors
8.2.5. PDE4 inhibitor
8.2.6. Phototherapy
8.2.7. Antibiotics
8.2.8. Antihistamines
8.2.9. Capsaicin
8.2.10. Systemic Agents for treating pruritus in AD
8.3. Self-care
8.3.1. Bathing Practices
8.3.2. Wet Wrap therapy (WWT)
8.3.3. Stress-Relieving Therapies
9. AD Clinical Guideline: American Academy of Dermatology Association (2014)
9.1. Guidelines for Diagnosis and Assessment
9.1.1. Recommendation for the diagnosis of AD
9.1.2. Recommendations for the use of biomarkers in the assessment of AD
9.1.3. Recommendations for disease severity and clinical outcomes assessment
9.1.4. Recommendations for the assessment of clinical associations of atopic dermatitis
9.2. Guidelines for management and treatment with Topical Therapies
9.2.1. Recommendations for non-pharmacologic interventions for the treatment of AD
9.2.2. Recommendations for use of topical corticosteroids for the treatment of AD
9.2.3. Recommendations for the use of TCIs for the treatment of AD
9.2.4. Recommendations for the use of topical antimicrobials and antiseptics for the treatment of AD
9.2.5. Recommendations for the use of topical antihistamines for the treatment of AD
9.3. Guidelines for Management with phototherapy and systemic agents
9.3.1. Recommendations for the use of phototherapy
9.3.2. Recommendations for the use of systemic immunomodulatory agents
9.3.3. Dosing and monitoring guidelines for the use of selected systemic agents
9.3.4. Recommendations for the use of systemic antimicrobials
9.3.5. Recommendations for the use of systemic antihistamines
9.4. Prevention of disease flares and use of adjunctive therapies and approaches
9.4.1. Recommendation for prevention of flares of AD
9.4.2. Recommendations for educational interventions for AD
9.4.3. Recommendations for testing for coexisting allergic disease
9.4.4. Recommendations for other adjunctive and complementary interventions for the treatment of atopic dermatitis
10. Atopic eczema in under 12s: Diagnosis and management by NICE (updated 2020)
10.1. Assessment of severity, psychological and psychosocial well being, and quality of life
10.1.1. Identification and management of trigger factors
10.2. Treatment
10.2.1. Recommendations for the use of Emollients
10.2.2. Recommendations for the use of Topical corticosteroids
10.2.3. Recommendations for the use of Topical calcineurin inhibitors
10.2.4. Recommendations for the use of Dry bandages and medicated dressings, including wet wrap therapy
10.2.5. Recommendations for the use of of antihistamines
10.2.6. Recommendations for the treatments for infections
10.2.7. Recommendations for the use of of phototherapy and systemic treatments
10.2.8. Recommendations for the use of complementary therapies
10.2.9. Recommendations for education and adherence to therapy
10.2.10 Recommendations of indications for referral
11. Consensus-based European guidelines for the treatment of atopic eczema in adults and children (2018)
11.1. Recommendations for Avoidance and Basic Therapy for AE
11.2. Recommendations for Emollient Therapy
11.3. Recommendations for Dietary Intervention
11.4. Recommendations for Topical anti‐inflammatory therapy
11.5. Recommendations for Antipruritic therapy
11.6. Recommendations for Antimicrobial therapy
11.7. Recommendations for Systemic anti‐inflammatory treatment
11.8. Recommendations for Biological agents
11.9. Recommendations for Other Systemic Treatment
11.10. Recommendations for Allergen‐specific immunotherapy (ASIT)
11.11. Recommendations for Complementary and alternative medicine in atopic eczema
12. Treatment Algorithm
12.1. Japanese Guidelines for Atopic Dermatitis 2020
12.2. Treatment Algorithm of AD in Early Childhood
13. Epidemiology and Patient Population
13.1. Key Findings
13.2. Epidemiology Methodology
13.3. 7MM Prevalent Population of Atopic dermatitis
13.4. 7MM Diagnosed Prevalent Population of Atopic dermatitis
13.5. Assumption and Rationale
13.5.1. United States
13.5.2. EU5
13.5.3. Japan
13.6. The United States
13.6.1. Diagnosed Prevalent Population of Atopic Dermatitis in the United States
13.6.2. Severity-specific distribution of Atopic Dermatitis in Adults in the United States
13.6.3. Severity-specific distribution of AD in Pediatric Population in the United States
13.6.4. Gender-specific Prevalence of Atopic Dermatitis in adults in the United States
13.6.5. Chronic Pruritus Prevalence in Atopic Dermatitis in Adults in the United States
13.7. EU5
13.7.1. Diagnosed Prevalent Population of Atopic Dermatitis in EU5
13.7.2. Severity-specific distribution of Atopic Dermatitis in Adults in EU5
13.7.3. Severity-specific distribution of Atopic Dermatitis in Pediatric Population in EU5
13.7.4. Gender-specific Cases of Atopic Dermatitis (AD) in EU5
13.7.5. Chronic Pruritus Prevalence in Atopic Dermatitis in Adults in EU5
13.8. Japan
13.8.1. Diagnosed Prevalent Population of Atopic Dermatitis in Japan
13.8.2. Severity-specific distribution of Atopic Dermatitis in Adults in Japan
13.8.3. Severity-specific distribution of Atopic Dermatitis in Pediatric Population in Japan
13.8.4. Gender-specific Prevalence of Atopic Dermatitis in adults in Japan
13.8.5. Chronic Pruritus Prevalence in Atopic Dermatitis in adults in Japan
14. Organizations contributing towards AD
15. Patient Journey
16. Marketed Drugs
16.1. Key Competitors
16.2. Dupixent (dupilumab): Sanofi/Regeneron Pharmaceuticals
16.2.1. Product Description
16.2.2. Current Pipeline Activity
16.2.3. Safety and Efficacy
16.3. Eucrisa (crisaborole): Pfizer
16.3.1. Product Description
16.3.2. Safety and Efficacy
16.4. Corectim Ointment: Japan Tobacco and Torii Pharmaceutical
16.4.1. Product Description
16.4.2. Current Pipeline Activity
16.4.3. Safety and Efficacy
16.5. Olumiant (baricitinib) &plusmn; TCS: Eli Lilly and Company
16.5.1. Product Description
16.5.2. Current Pipeline Activity
16.5.3. Safety and Efficacy
16.6. Rinvoq (upadacitinib): AbbVie
16.6.1. Product Description
16.6.2. Clinical Development
16.6.3. Safety and Efficacy
16.7. Cibinqo (abrocitinib): Pfizer
16.7.1. Product Description
16.7.2. Clinical Development
16.7.3. Safety and Efficacy
16.8. Adtralza (tralokinumab): LEO Pharma
16.8.1. Product Description
16.8.2. Current Pipeline Activity
16.8.3. Safety and Efficacy
16.9. Opzelura (Ruxolitinib): Incyte Corporation
16.9.1. Product Description
16.9.2. Clinical Development
16.9.3. Safety and Efficacy
17. Emerging Drugs
17.1. Key Competitors
17.2. Ly3650150: Eli Lilly and Company
17.2.1. Product Description
17.2.2. Clinical Development
17.2.3. Safety and Efficacy
17.3. Etrasimod: Arena Pharmaceuticals
17.3.1. Product Description
17.3.2. Clinical Development
17.3.3. Safety and Efficacy
17.4. FB825: Oneness Biotech
17.4.1. Product Description
17.4.2. Clinical Development
17.4.3. Safety and Efficacy
17.5. Nemolizumab: Galderma
17.5.1. Product Description
17.5.2. Clinical Development
17.5.3. Safety and Efficacy
17.6. Difamilast: Otsuka Pharmaceutical
17.6.1. Product Description
17.6.2. Clinical Development
17.6.3. Safety and Efficacy
17.7. DS107: DS Biopharma
17.7.1. Product Description
17.7.2. Clinical Development
17.7.3. Safety and Efficacy
17.8. Bermekimab: Janssen
17.8.1. Product Description
17.8.2. Clinical Development
17.8.3. Safety and Efficacy
17.9. B244: AOBiome Therapeutics
17.9.1. Product Description
17.9.2. Clinical Development
17.9.3. Safety and Efficacy
17.10. KY1005 (Amlitelimab): Sanofi/Kymab
17.10.1. Product Description
17.10.2. Clinical Development
17.10.3. Safety and Efficacy
17.11. Q301: Qurient
17.11.1. Product Description
17.11.2. Clinical Development
17.11.3. Safety and Efficacy
17.12. Roflumilast: Arcutis Biotherapeutics
17.12.1. Product Description
17.12.2. Clinical Development
17.12.3. Safety and Efficacy
17.13. Difelikefalin (Korsuva): Cara Therapeutics
17.13.1. Product Description
17.13.2. Clinical Development
17.13.3. Safety and Efficacy
17.14. Tradipitant: Vanda Pharmaceuticals
17.14.1. Product Description
17.14.2. Clinical Development
17.14.3. Safety and Efficacy
18. Potential of Current Therapies and Emerging Therapies
19. Atopic Dermatitis: Seven Major Market Analysis
19.1. Key Findings
19.2. Market Methodology
19.3. Market Size of Atopic Dermatitis in the 7MM
19.4. Market Outlook
19.5. Attribute Analysis
19.6. Key Market Forecast Assumptions
19.7. United States Market Size
19.7.1. Total Market size of AD
19.7.2. Market Size of Atopic Dermatitis by Current Therapies
19.7.3. Market Size of Atopic Dermatitis by Emerging Therapies
19.8. EU-5 Market Size
19.8.1. Total Market size of AD
19.8.2. Market Size of Atopic Dermatitis by Current Therapies
19.8.3. Market Size of Atopic Dermatitis by Emerging Therapies
19.9. Japan Market Size
19.9.1. Total Market size of AD
19.9.2. Market Size of Atopic Dermatitis by Current Therapies
19.9.3. Market Size of Atopic Dermatitis by Emerging Therapies
20. Market Drivers
21. Market Barriers
22. Unmet Needs
23. KOL Views
24. Market Access and Reimbursement
24.1. United States
24.2. Germany
24.3. United Kingdom
24.4. France
24.5. Italy
24.6. Spain
24.7. Japan
25. Appendix
25.1. Bibliography
25.2. Report Methodology
26. DelveInsight Capabilities
27. Disclaimer
28. About DelveInsight

DelveInsight’s ‘Atopic Dermatitis (AD) - Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Atopic Dermatitis (AD), historical and forecasted epidemiology as well as the Atopic Dermatitis (AD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Atopic Dermatitis Market 

Atopic Dermatitis Market Insight, Epidemiology and Market Forecast -2030

DelveInsight’s Atopic Dermatitis Market Insights, Epidemiology and Market Forecast - 2030 report provides the detailed overview of the disease and in depth understanding of historical..